Better Science, Better Health

“Better Science, Better Health” was established by Vital Transformation to facilitate international collaboration in new clinical regulatory pathways, sources of evidence, and harnessing real world data to improve the access of needed new medicines by patients.

“Better Science, Better Health” provides a unique opportunity for international thought leaders to engage directly in these initiatives around the world, while also bringing new relevant voices into the process.

“Better Science, Better Health” has three core areas of focus:

  • Harnessing real world evidence for better decision-making and create better patient outcomes
  • Implementing new development pathways and evidence generation to improve access to needed new therapies for patients
  • Developing best practices, successes, and opportunities for the integration of patient data and analytics to identify new medicines

Latest Events

The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation?

Wednesday, June 5, 2019
1:45 PM - 2:45 PM
BIO International Convention - Philadelphia, PA


Following Vital Transformation's research on investment success factors for biotech companies released at the European Health Forum Gastein, this session will present original research modelling the potential impact both short and long term for patients, payers, and industry for such proposals, and show how the IPI can impact access and innovation broadly. As well, our panellists will place the IPI into the context of other models currently being investigated internationally such as value based payments, managed entry agreements, and adaptive pathways.

More Info

Investing in EU Biotech IP – What Works?

4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET

In this webinar we:
• Highlight the results of the research
• Expand on the datapackage used
• Discuss the gap between EU and US IP productivity in healthcare
• Address the need for IP in the global biotech sector

Download Video & Slides

Supporting IP in Europe


Vital Transformation leads a new consortia investigating the relationship between public funding and private investment into new innovative therapies and the supporting system of IP.

This project will develop original research investigating the success factors that create successful EU biotech companies and communicate the importance of IP in creating an ecosystem where investors are willing to lose everything 92% of the time, in order to fund the 8% of medical breakthroughs that succeed.

More Info

VIEW ALL EVENTS

Latest News

US Biotech Lobby Slams EU Reference Pricing

By CARMEN PAUN 4/9/19,
© POLITICO PRO Healthcare

U.S. biotechnology lobby BIO said the Trump administration’s proposal to peg the prices of certain drugs to a basket of mostly EU reference countries would lead to a “downward spiral” that would negatively affect the development of new medicines.

Don’t Believe the Hype – International Reference Pricing Will Cost Far More than 1% of R&D Budgets

By Duane Schulthess

It’s odd that a city like Brussels managed to carve itself out a niche as one of the major political centres of the world. The medieval site of a notoriously typhus infested bog, one of the main streets in downtown, ‘Rue du Marais’, literally means, “Street of the Swamp” and the name of the city itself comes from the old Flemish word Broekzele, which roughly translates to ‘settlement in the swamp.’ So, when one talks politically of draining the swamp, at least in Brussels, it carries a literal interpretation that is often distant from the current political climate in DC.

VIEW ALL NEWS

Newsletter

Register now to receive all the latest news and events.

SIGN UP

Latest Research

Our consultancy services

Videos

Visit our youtube channel to view all of our videos.

Webinar: "Investing in EU Biotech IP – What Works?" 4 Dec 2018

An HTA perspective on the Acceptability of Real World Evidence and Methods to Enhance its use final